Eric M Ramos1, Socorro Harb2, Joan Dragavon2, Paul Swenson3, Joanne D Stekler4, Robert W Coombs5. 1. Department of Laboratory Medicine, University of Washington, Seattle, WA, United States. Electronic address: emramos@uw.edu. 2. Department of Laboratory Medicine, University of Washington, Seattle, WA, United States. 3. Department of Laboratory Medicine, University of Washington, Seattle, WA, United States; Public Health - Seattle and King County, United States. 4. Public Health - Seattle and King County, United States; Department of Medicine, University of Washington, Seattle, WA, United States. 5. Department of Laboratory Medicine, University of Washington, Seattle, WA, United States; Department of Medicine, University of Washington, Seattle, WA, United States.
Abstract
BACKGROUND: The ARCHITECT HIV Ag/Ab Combo assay has a wide dynamic range for determining the sample-to-cutoff ratio (S/CO) values compared to other diagnostic HIV antibody assays. OBJECTIVES: Determine the performance of an HIV testing algorithm that uses the ARCHITECT combo assay in the clinical setting and explore the utility of the signal-to-cutoff (S/CO) ratio to predict acute HIV-1 infection status. STUDY DESIGN: A retrospective analysis of clinical samples from a hospital and referral population screened for HIV-1 infection between May 2011 and March 2013. Repeatedly reactive samples were tested using the Multispot HIV-1/HIV-2 rapid test and depending on that result, confirmatory orthogonal testing used the Western blot (WB) for HIV-1, Immunoblot for HIV-2 and nucleic acid amplification testing (NAAT) for HIV RNA. RESULTS: A total of 21,317 test results were evaluated of which 509 were ARCHITECT repeatedly reactive; of these, 422 were Multispot-reactive only for HIV-1 (413 WB-positive; 9 indeterminate), 4 were Multispot-reactive for both HIV-1 and HIV-2 (one HIV-2 immunoblot-positive with 17 HIV-2 RNA copies/mL) and 83 were Multispot-non-reactive of which 15 were HIV-1 RNA positive and represented acute HIV-1 infection. There was an association among the ARCHITECT S/CO (median; IQR) values for antibody-negative (0.14; 0.11-0.16), acute infection (33; 2.1-76) and established HIV-1 infection (794; 494-1,029) (Kruskal-Wallis, p<0.0001). CONCLUSIONS: The ARCHITECT combo assay with Multispot confirmation and reserved use of HIV-1 WB, HIV-2 Immunoblot and HIV NAAT for Multispot dual HIV-1/2 infection, and NAAT alone for Multispot-negative specimens, had a suitable test performance for detecting acute and established HIV infection.
BACKGROUND: The ARCHITECT HIV Ag/Ab Combo assay has a wide dynamic range for determining the sample-to-cutoff ratio (S/CO) values compared to other diagnostic HIV antibody assays. OBJECTIVES: Determine the performance of an HIV testing algorithm that uses the ARCHITECT combo assay in the clinical setting and explore the utility of the signal-to-cutoff (S/CO) ratio to predict acute HIV-1 infection status. STUDY DESIGN: A retrospective analysis of clinical samples from a hospital and referral population screened for HIV-1 infection between May 2011 and March 2013. Repeatedly reactive samples were tested using the Multispot HIV-1/HIV-2 rapid test and depending on that result, confirmatory orthogonal testing used the Western blot (WB) for HIV-1, Immunoblot for HIV-2 and nucleic acid amplification testing (NAAT) for HIV RNA. RESULTS: A total of 21,317 test results were evaluated of which 509 were ARCHITECT repeatedly reactive; of these, 422 were Multispot-reactive only for HIV-1 (413 WB-positive; 9 indeterminate), 4 were Multispot-reactive for both HIV-1 and HIV-2 (one HIV-2 immunoblot-positive with 17 HIV-2 RNA copies/mL) and 83 were Multispot-non-reactive of which 15 were HIV-1 RNA positive and represented acute HIV-1 infection. There was an association among the ARCHITECT S/CO (median; IQR) values for antibody-negative (0.14; 0.11-0.16), acute infection (33; 2.1-76) and established HIV-1 infection (794; 494-1,029) (Kruskal-Wallis, p<0.0001). CONCLUSIONS: The ARCHITECT combo assay with Multispot confirmation and reserved use of HIV-1 WB, HIV-2 Immunoblot and HIVNAAT for Multispot dual HIV-1/2 infection, and NAAT alone for Multispot-negative specimens, had a suitable test performance for detecting acute and established HIV infection.
Authors: Silvina Masciotra; J Steven McDougal; Jane Feldman; Patrick Sprinkle; Laura Wesolowski; S Michele Owen Journal: J Clin Virol Date: 2011-10-05 Impact factor: 3.168
Authors: Kimberly A Powers; Azra C Ghani; William C Miller; Irving F Hoffman; Audrey E Pettifor; Gift Kamanga; Francis Ea Martinson; Myron S Cohen Journal: Lancet Date: 2011-07-16 Impact factor: 79.321
Authors: Joanne D Stekler; Paul D Swenson; Robert W Coombs; Joan Dragavon; Katherine K Thomas; Catherine A Brennan; Sushil G Devare; Robert W Wood; Matthew R Golden Journal: Clin Infect Dis Date: 2009-08-01 Impact factor: 9.079
Authors: Elizabeth A DiNenno; Joseph Prejean; Kevin P Delaney; Kristina Bowles; Tricia Martin; Amrita Tailor; Gema Dumitru; Mary M Mullins; Angela Hutchinson; Amy Lansky Journal: Public Health Rep Date: 2017-11-28 Impact factor: 2.792
Authors: Mark M Manak; Linda L Jagodzinski; Ashley Shutt; Jennifer A Malia; Mike Leos; Jason Ouellette; Siriwat Akapirat; Donn L Colby; Nittaya Phanuphak; Leigh Anne Eller; Merlin L Robb; Mark de Souza; Jintanat Ananworanich; Sheila A Peel Journal: J Clin Microbiol Date: 2019-09-24 Impact factor: 5.948
Authors: Kara G Marson; Robert Marlin; Phong Pham; Stephanie E Cohen; Diane Jones; Marguerite Roemer; Philip J Peters; Barbara Haller; Christopher D Pilcher Journal: J Clin Virol Date: 2017-04-07 Impact factor: 3.168
Authors: C R Robert George; Peter W Robertson; M Josephine Lusk; Ross Whybin; William Rawlinson Journal: J Clin Microbiol Date: 2014-09-10 Impact factor: 5.948
Authors: Kelly A Curtis; Donna L Rudolph; Yi Pan; Kevin Delaney; Kathryn Anastos; Jack DeHovitz; Seble G Kassaye; Carl V Hanson; Audrey L French; Elizabeth Golub; Adaora A Adimora; Igho Ofotokun; Hector Bolivar; Mirjam-Colette Kempf; Philip J Peters; William M Switzer Journal: PLoS One Date: 2021-07-01 Impact factor: 3.240